The non-steroidal mineralocorticoid receptor antagonist finerenone and heart failure with preserved ejection fraction
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The non-steroidal mineralocorticoid receptor antagonist finerenone and heart failure with preserved ejection fraction
Authors
Keywords
-
Journal
Cardiovascular Diabetology
Volume 22, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-06-30
DOI
10.1186/s12933-023-01899-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Spironolactone effect on circulating procollagen type I carboxy-terminal propeptide: Pooled analysis of three randomized trials
- (2023) João Pedro Ferreira et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Benefits of the Non-Steroidal Mineralocorticoid Receptor Antagonist Finerenone in Metabolic Syndrome-Related Heart Failure with Preserved Ejection Fraction
- (2023) Ixchel Lima-Posada et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- An analysis of DPV and DIVE registry patients with chronic kidney disease according to the finerenone phase III clinical trial selection criteria
- (2023) Peter Bramlage et al. Cardiovascular Diabetology
- Heart Failure With Preserved Ejection Fraction
- (2023) Margaret M. Redfield et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO‐DKD trial
- (2022) Gerasimos Filippatos et al. EUROPEAN JOURNAL OF HEART FAILURE
- SGLT2 inhibitors and finerenone: one or the other or both?
- (2022) Brendon L Neuen et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Finerenone Reduces Renal RORγt γδ T Cells and Protects against Cardiorenal Damage
- (2022) Katja Luettges et al. AMERICAN JOURNAL OF NEPHROLOGY
- Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE)
- (2022) Jennifer B Green et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trials
- (2022) João Pedro Ferreira et al. EUROPEAN JOURNAL OF HEART FAILURE
- Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
- (2022) Scott D. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Steroidal MRA Across the Spectrum of Renal Function
- (2022) João Pedro Ferreira et al. JACC-Heart Failure
- Finerenone and Heart Failure Outcomes by Kidney Function/Albuminuria in Chronic Kidney Disease and Diabetes
- (2022) Gerasimos Filippatos et al. JACC-Heart Failure
- Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease
- (2022) Yaofu Zhang et al. Cardiovascular Diabetology
- Phenomapping in heart failure with preserved ejection fraction: insights, limitations, and future directions
- (2022) Anthony E Peters et al. CARDIOVASCULAR RESEARCH
- Cellular and molecular pathobiology of heart failure with preserved ejection fraction
- (2021) Sumita Mishra et al. Nature Reviews Cardiology
- From Systemic Inflammation to Myocardial Fibrosis
- (2021) Walter J. Paulus et al. CIRCULATION RESEARCH
- Effect of KBP-5074 on Blood Pressure in Advanced Chronic Kidney Disease: Results of the BLOCK-CKD Study
- (2021) George Bakris et al. HYPERTENSION
- Mineralocorticoid receptor blockade with finerenone improves heart function and exercise capacity in ovariectomized mice
- (2021) Marie Pieronne‐Deperrois et al. ESC Heart Failure
- Heart failure with preserved ejection fraction in humans and mice: embracing clinical complexity in mouse models
- (2021) Coenraad Withaar et al. EUROPEAN HEART JOURNAL
- 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
- (2021) Theresa A McDonagh et al. EUROPEAN HEART JOURNAL
- Hypertension and heart failure with preserved ejection fraction: position paper by the European Society of Hypertension
- (2021) Alexandros Kasiakogias et al. JOURNAL OF HYPERTENSION
- Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes
- (2021) Bertram Pitt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Empagliflozin in Heart Failure with a Preserved Ejection Fraction
- (2021) Stefan D. Anker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Novel non‐steroidal mineralocorticoid receptor antagonists in cardiorenal disease
- (2021) Ulrich Kintscher et al. BRITISH JOURNAL OF PHARMACOLOGY
- Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial
- (2021) Gerasimos Filippatos et al. CIRCULATION
- Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis
- (2021) Rajiv Agarwal et al. EUROPEAN HEART JOURNAL
- Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders − New perspectives for combination therapy
- (2021) Peter Kolkhof et al. PHARMACOLOGICAL RESEARCH
- Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction
- (2020) Jordana B. Cohen et al. JACC-Heart Failure
- Epidemiology of heart failure
- (2020) Amy Groenewegen et al. EUROPEAN JOURNAL OF HEART FAILURE
- Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
- (2020) Rajiv Agarwal et al. EUROPEAN HEART JOURNAL
- Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
- (2020) George L. Bakris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 1 Studies to Define the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Profiles of the Nonsteroidal Mineralocorticoid Receptor Antagonist Apararenone in Healthy Volunteers
- (2020) Tadakatsu Nakamura et al. Clinical Pharmacology in Drug Development
- Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN)
- (2020) Sadayoshi Ito et al. Clinical Journal of the American Society of Nephrology
- Heart Failure With Preserved Ejection Fraction Infrequently Evolves Toward a Reduced Phenotype in Long-Term Survivors
- (2019) Josep Lupón et al. Circulation-Heart Failure
- How to diagnose heart failure with preserved ejection fraction: the HFA–PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)
- (2019) Burkert Pieske et al. EUROPEAN HEART JOURNAL
- Survival of patients with chronic heart failure in the community: a systematic review and meta‐analysis
- (2019) Nicholas R. Jones et al. EUROPEAN JOURNAL OF HEART FAILURE
- Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
- (2019) Scott D. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phenomapping of patients with heart failure with preserved ejection fraction using machine learning‐based unsupervised cluster analysis
- (2019) Matthew W. Segar et al. EUROPEAN JOURNAL OF HEART FAILURE
- Double-Blind Randomized Phase 3 Study Comparing Esaxerenone (CS-3150) and Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study)
- (2019) Sadayoshi Ito et al. HYPERTENSION
- A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure with Preserved Ejection Fraction
- (2018) Yogesh N. V. Reddy et al. CIRCULATION
- Short- and long-term administration of the non-steroidal mineralocorticoid receptor antagonist finerenone opposes metabolic syndrome-related cardio-renal dysfunction
- (2018) Marianne Lachaux et al. DIABETES OBESITY & METABOLISM
- Pharmacokinetics of the Novel, Selective, Non-steroidal Mineralocorticoid Receptor Antagonist Finerenone in Healthy Volunteers: Results from an Absolute Bioavailability Study and Drug–Drug Interaction Studies In Vitro and In Vivo
- (2018) Roland Heinig et al. EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS
- Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone’s Antifibrotic ActivityNovelty and Significance
- (2018) Jana Grune et al. HYPERTENSION
- Incident Hyperkalemia, Hypokalemia, and Clinical Outcomes During Spironolactone Treatment of Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT Trial
- (2018) Akshay S. Desai et al. JOURNAL OF CARDIAC FAILURE
- Preclinical pharmacology of AZD9977: A novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion
- (2018) Krister Bamberg et al. PLoS One
- Pharmacokinetics, Metabolism, and Excretion of [14C]Esaxerenone, a Novel Mineralocorticoid Receptor Blocker in Humans
- (2018) Makiko Yamada et al. DRUG METABOLISM AND DISPOSITION
- 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development
- (2017) Peter Kolkhof et al. JOURNAL OF ENDOCRINOLOGY
- A Test in Context: Myocardial Strain Measured by Speckle-Tracking Echocardiography
- (2017) Patrick Collier et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Spironolactone Metabolites in TOPCAT — New Insights into Regional Variation
- (2017) Simon de Denus et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction
- (2017) Inder S. Anand et al. JACC-Heart Failure
- Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction
- (2016) Sanjiv J. Shah et al. CIRCULATION
- A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease
- (2016) Gerasimos Filippatos et al. EUROPEAN HEART JOURNAL
- A tentative interpretation of the TOPCAT trial based on randomized evidence from the brain natriuretic peptide stratum analysis
- (2016) Nicolas Girerd et al. EUROPEAN JOURNAL OF HEART FAILURE
- Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists Cause Differential Cardiac Gene Expression in Pressure Overload-induced Cardiac Hypertrophy
- (2016) Jana Grune et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Treatment of Heart Failure With Preserved Ejection Fraction
- (2016) Marc A. Pfeffer et al. JAMA Cardiology
- Nonsteroidal antagonists of the mineralocorticoid receptor
- (2015) Peter Kolkhof et al. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
- Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction
- (2015) Scott D. Solomon et al. EUROPEAN HEART JOURNAL
- Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response
- (2015) David P. Kao et al. EUROPEAN JOURNAL OF HEART FAILURE
- Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist
- (2015) Kiyoshi Arai et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1
- (2015) Larbi Amazit et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects From Rat Cardiorenal Injury
- (2014) Peter Kolkhof et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Spironolactone for Heart Failure with Preserved Ejection Fraction
- (2014) Bertram Pitt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial
- (2013) Bertram Pitt et al. EUROPEAN HEART JOURNAL
- Effect of Spironolactone on Diastolic Function and Exercise Capacity in Patients With Heart Failure With Preserved Ejection Fraction
- (2013) Frank Edelmann et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Discovery of BAY 94-8862: A Nonsteroidal Antagonist of the Mineralocorticoid Receptor for the Treatment of Cardiorenal Diseases
- (2012) Lars Bärfacker et al. ChemMedChem
- Molecular pharmacology of the mineralocorticoid receptor: Prospects for novel therapeutics
- (2011) Peter Kolkhof et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- SnapShot: Nuclear Receptors I
- (2010) Neil J. McKenna et al. CELL
- Epidemiology and clinical course of heart failure with preserved ejection fraction
- (2010) Carolyn S.P. Lam et al. EUROPEAN JOURNAL OF HEART FAILURE
- A New Mode of Mineralocorticoid Receptor Antagonism by a Potent and Selective Nonsteroidal Molecule
- (2010) Jérôme Fagart et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms
- (2010) Faiez Zannad et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation